WallStreetZenWallStreetZen

NASDAQ: GH
Guardant Health Inc Stock

$20.63+2.67 (+14.87%)
Updated Mar 28, 2024
GH Price
$20.63
Fair Value Price
$23.12
Market Cap
$2.51B
52 Week Low
$16.92
52 Week High
$41.06
P/E
-4.82x
P/B
15.82x
P/S
5.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$563.95M
Earnings
-$479.45M
Gross Margin
59.7%
Operating Margin
-84.44%
Profit Margin
-85%
Debt to Equity
10.26
Operating Cash Flow
-$325M
Beta
1.34
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GH Overview

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GH ($20.63) is undervalued by 10.77% relative to our estimate of its Fair Value price of $23.12 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GH ($20.63) is not significantly undervalued (10.77%) relative to our estimate of its Fair Value price of $23.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GH due diligence checks available for Premium users.

Be the first to know about important GH news, forecast changes, insider trades & much more!

GH News

Valuation

GH fair value

Fair Value of GH stock based on Discounted Cash Flow (DCF)
Price
$20.63
Fair Value
$23.12
Undervalued by
10.77%
GH ($20.63) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GH ($20.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.82x
Industry
37.37x
Market
44.51x

GH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
15.82x
Industry
4.38x
GH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GH's financial health

Profit margin

Revenue
$155.1M
Net Income
-$187.0M
Profit Margin
-120.6%
GH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.8B
Liabilities
$1.6B
Debt to equity
10.26
GH's short-term assets ($1.35B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GH's long-term liabilities ($1.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$78.7M
Investing
$663.5M
Financing
$90.6M
GH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GH vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
GH$2.51B+14.87%-4.82x15.82x
OLK$2.92B-0.38%-94.04x5.82x
NEO$2.01B+3.42%-22.46x2.13x
TWST$1.98B-0.49%-9.50x3.36x
MYGN$1.92B-0.37%-6.70x2.45x

Guardant Health Stock FAQ

What is Guardant Health's quote symbol?

(NASDAQ: GH) Guardant Health trades on the NASDAQ under the ticker symbol GH. Guardant Health stock quotes can also be displayed as NASDAQ: GH.

If you're new to stock investing, here's how to buy Guardant Health stock.

What is the 52 week high and low for Guardant Health (NASDAQ: GH)?

(NASDAQ: GH) Guardant Health's 52-week high was $41.06, and its 52-week low was $16.92. It is currently -49.76% from its 52-week high and 21.96% from its 52-week low.

How much is Guardant Health stock worth today?

(NASDAQ: GH) Guardant Health currently has 121,712,724 outstanding shares. With Guardant Health stock trading at $20.63 per share, the total value of Guardant Health stock (market capitalization) is $2.51B.

Guardant Health stock was originally listed at a price of $32.20 in Oct 4, 2018. If you had invested in Guardant Health stock at $32.20, your return over the last 5 years would have been -35.93%, for an annualized return of -8.52% (not including any dividends or dividend reinvestments).

How much is Guardant Health's stock price per share?

(NASDAQ: GH) Guardant Health stock price per share is $20.63 today (as of Mar 28, 2024).

What is Guardant Health's Market Cap?

(NASDAQ: GH) Guardant Health's market cap is $2.51B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Guardant Health's market cap is calculated by multiplying GH's current stock price of $20.63 by GH's total outstanding shares of 121,712,724.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.